Rodríguez-Otero is medical coordinator of the Central Unit for Clinical Trials; associate clinical professor, preclinical and ...

LINKER-MM4 trial shows linvoseltamab monotherapy achieves a 79% overall response rate in newly diagnosed MM patients, with 92 ...

SAN DIEGO -- The risk of progression from smoldering multiple myeloma to symptomatic disease decreased by 50% in patients treated with the anti-CD38 monoclonal antibody daratumumab (Darzalex), ...

KRd regimen significantly improved PFS over VRd in newly diagnosed multiple myeloma, reducing progression or death risk by 43%. Consistent benefits of KRd were observed across cytogenetic subgroups, ...

Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center have uncovered biological differences ...

Iberdomide and mezigdomide are currently being evaluated for the treatment of patients with multiple myeloma in a number of ...

Among patients who were newly diagnosed with multiple myeloma, Kyprolis (carfilzomib) plus Revlimid (lenalidomide) and dexamethasone (KRd) was associated with improvements in progression-free survival ...

Data show that patients’ multiple myeloma still fails to progress if patients receive less-frequent Tecvayli. A reduced dosing schedule of Tecvayli (teclistamab) continued to slow the progression of ...

Please provide your email address to receive an email when new articles are posted on . The diet intervention appeared safe and feasible. It also improved quality of life and exhibited favorable ...

In a step forward for bispecific antibodies, study results presented at ASH suggest a Tecvayli-based combination could have ...

A proposed combination of Johnson & Johnson’s multiple myeloma bispecific Tecvayli has turned up positive trial data that ...

Annual Meeting, held December 6-9, 2025, in Orlando, Florida, showcased groundbreaking clinical advances in multiple myeloma ...